CSL
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The last earnings update was 70 days ago. More info.
Add to Portfolio Compare Print
CSL Share Price and Events
7 Day Returns
1 Year Returns
CSL Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| CSL (CSL) | -3.2% | -3.5% | -3.6% | 17.7% | 82.4% | 180.2% |
| AU Biotechs | -2.7% | -3% | -1.7% | 19.4% | 77.2% | 155.6% |
| AU Market | -0% | 1% | 6.9% | 4.6% | 18.2% | 4.8% |
1 Year Return vs Industry and Market
- CSL underperformed the Biotechs industry which returned 19.4% over the past year.
- CSL outperformed the Market in Australia which returned 4.6% over the past year.
Price Volatility
Related Companies
CSL Value
Is CSL undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
CSL
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for CSL.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 12 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 10.4% |
| Perpetual Growth Rate | 10-Year AU Government Bond Rate | 2.3% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year AU Govt Bond Rate | 2.3% |
| Equity Risk Premium | S&P Global | 6% |
| Biotechs Unlevered Beta | Simply Wall St/ S&P Global | 1.45 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.449 (1 + (1- 30%) (7.55%)) |
1.352 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
1.35 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.31% + (1.352 * 5.96%) |
10.37% |
Discounted Cash Flow Calculation for ASX:CSL using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for CSL is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (USD, Millions) | Source |
Present Value Discounted (@ 10.37%) |
|
|---|---|---|---|
| 2019 | 844.79 | Analyst x3 | 765.41 |
| 2020 | 1,104.09 | Analyst x3 | 906.35 |
| 2021 | 1,178.77 | Analyst x2 | 876.73 |
| 2022 | 1,818.22 | Analyst x1 | 1,225.27 |
| 2023 | 2,139.04 | Est @ 17.64% | 1,306.02 |
| 2024 | 2,418.07 | Est @ 13.04% | 1,337.66 |
| 2025 | 2,655.65 | Est @ 9.82% | 1,331.04 |
| 2026 | 2,856.71 | Est @ 7.57% | 1,297.28 |
| 2027 | 3,027.92 | Est @ 5.99% | 1,245.83 |
| 2028 | 3,175.95 | Est @ 4.89% | 1,183.95 |
| Present value of next 10 years cash flows | $11,475.52 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= $3,175.95 × (1 + 2.31%) ÷ (10.37% – 2.31%) |
$40,321.06 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= $40,321.06 ÷ (1 + 10.37%)10 |
$15,031.12 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= $11,475.52 + $15,031.12 |
$26,506.65 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $26,506.65 / 453.10 |
$58.5 |
| Calculation | Result | |
|---|---|---|
| Exchange Rate | USD/AUD
(Reporting currency to currency of ASX:CSL) |
1.402 |
| Value per Share (AUD) |
= Value per Share in USD x Exchange Rate (USD/AUD)
= $58.5 x 1.402 |
A$82.02 |
| Value per share (AUD) | From above. | A$82.02 |
| Current discount | Discount to share price of
A$190.37
= -1 x (A$190.37 - A$82.02) / A$82.02 |
-132.1% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
- The current share price of CSL is above its future cash flow value.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for CSL's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
CSL's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in USD | $3.98 |
| ASX:CSL Share Price ** | ASX (2019-04-23) in AUD | A$190.37 |
| ASX:CSL Share Price converted to USD reporting currency | Exchange rate (AUD/ USD) 0.713 | $135.77 |
| Global Biotechs Industry PE Ratio | Median Figure of 78 Publicly-Listed Biotechs Companies | 21.37x |
| Australia Market PE Ratio | Median Figure of 544 Publicly-Listed Companies | 16.14x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of CSL.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = ASX:CSL Share Price ÷ EPS (both in USD) = 135.77 ÷ 3.98 |
34.08x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- CSL is overvalued based on earnings compared to the Global Biotechs industry average.
- CSL is overvalued based on earnings compared to the Australia market.
Price based on expected Growth
Does
CSL's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 34.08x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts |
9.1%per year |
| Global Biotechs Industry PEG Ratio | Median Figure of 57 Publicly-Listed Biotechs Companies | 1.48x |
| Australia Market PEG Ratio | Median Figure of 360 Publicly-Listed Companies | 1.35x |
*Line of best fit is calculated by linear regression .
| Calculation | Outcome | |
|---|---|---|
| PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 34.08x ÷ 9.1% |
3.73x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- CSL is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on
CSL's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in USD | $10.71 |
| ASX:CSL Share Price * | ASX (2019-04-23) in AUD | A$190.37 |
| ASX:CSL Share Price converted to USD reporting currency | Exchange rate (AUD/ USD) 0.713 | $135.77 |
| Australia Biotechs Industry PB Ratio | Median Figure of 45 Publicly-Listed Biotechs Companies | 3.45x |
| Australia Market PB Ratio | Median Figure of 1,676 Publicly-Listed Companies | 1.67x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = ASX:CSL Share Price ÷ Book Value per Share (both in USD) = 135.77 ÷ 10.71 |
12.67x |
* Primary Listing of CSL.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- CSL is overvalued based on assets compared to the AU Biotechs industry average.
Value checks
We assess CSL's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) CSL has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
CSL Future Performance
How is CSL expected to perform in the next 1 to 3 years based on estimates from 12 analysts?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- CSL's earnings growth is expected to exceed the low risk savings rate of 2.3%.
Growth vs Market Checks
- CSL's earnings growth is expected to exceed the Australia market average.
- CSL's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| ASX:CSL Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts | 9.1% |
| ASX:CSL Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 12 Analysts | 7.1% |
| Australia Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 10.9% |
| Australia Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 8.5% |
| Australia Market Earnings Growth Rate | Market Cap Weighted Average | 6.7% |
| Australia Market Revenue Growth Rate | Market Cap Weighted Average | 3% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 12 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-06-30 | 11,531 | 2,724 | 1 | |
| 2022-06-30 | 10,686 | 2,723 | 2,549 | 2 |
| 2021-06-30 | 9,821 | 2,484 | 2,329 | 10 |
| 2020-06-30 | 9,208 | 2,297 | 2,142 | 12 |
| 2019-06-30 | 8,555 | 1,957 | 1,920 | 12 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 8,274 | 1,597 | 1,803 |
| 2018-09-30 | 8,094 | 1,750 | 1,766 |
| 2018-06-30 | 7,915 | 1,902 | 1,729 |
| 2018-03-31 | 7,666 | 1,662 | 1,674 |
| 2017-12-31 | 7,417 | 1,422 | 1,618 |
| 2017-09-30 | 7,182 | 1,335 | 1,478 |
| 2017-06-30 | 6,947 | 1,247 | 1,337 |
| 2017-03-31 | 6,802 | 1,192 | 1,333 |
| 2016-12-31 | 6,656 | 1,138 | 1,329 |
| 2016-09-30 | 6,386 | 1,158 | 1,286 |
| 2016-06-30 | 6,115 | 1,179 | 1,242 |
| 2016-03-31 | 5,983 | 1,296 | 1,324 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 12 Analyst Estimates (S&P Global) | See Below |
All data from CSL Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-06-30 | 6.06 | 6.06 | 6.06 | 1.00 |
| 2022-06-30 | 5.63 | 5.63 | 5.63 | 2.00 |
| 2021-06-30 | 5.14 | 5.61 | 4.84 | 7.00 |
| 2020-06-30 | 4.74 | 5.00 | 4.51 | 9.00 |
| 2019-06-30 | 4.24 | 4.35 | 4.14 | 9.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2018-12-31 | 3.98 |
| 2018-09-30 | 3.90 |
| 2018-06-30 | 3.82 |
| 2018-03-31 | 3.69 |
| 2017-12-31 | 3.57 |
| 2017-09-30 | 3.25 |
| 2017-06-30 | 2.94 |
| 2017-03-31 | 2.92 |
| 2016-12-31 | 2.90 |
| 2016-09-30 | 2.80 |
| 2016-06-30 | 2.69 |
| 2016-03-31 | 2.85 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess CSL's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
CSL has a total score of 4/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
CSL Past Performance
How has CSL performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- CSL's year on year earnings growth rate has been positive over the past 5 years.
- CSL's 1-year earnings growth exceeds its 5-year average (11.4% vs 6.4%)
- CSL's earnings growth has not exceeded the Global Biotechs industry average in the past year (11.4% vs 19%).
Earnings and Revenue History
All data from CSL Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 8,273.50 | 1,803.30 | 1,440.90 | 750.50 |
| 2018-09-30 | 8,094.40 | 1,766.10 | 1,370.95 | 726.45 |
| 2018-06-30 | 7,915.30 | 1,728.90 | 1,301.00 | 702.40 |
| 2018-03-31 | 7,666.20 | 1,673.55 | 1,250.70 | 712.60 |
| 2017-12-31 | 7,417.10 | 1,618.20 | 1,200.40 | 722.80 |
| 2017-09-30 | 7,182.05 | 1,477.80 | 1,191.10 | 694.85 |
| 2017-06-30 | 6,947.00 | 1,337.40 | 1,181.80 | 666.90 |
| 2017-03-31 | 6,801.55 | 1,333.25 | 1,118.45 | 641.90 |
| 2016-12-31 | 6,656.10 | 1,329.10 | 1,055.10 | 616.90 |
| 2016-09-30 | 6,385.70 | 1,285.75 | 1,033.15 | 615.35 |
| 2016-06-30 | 6,115.30 | 1,242.40 | 1,011.20 | 613.80 |
| 2016-03-31 | 5,982.75 | 1,324.00 | 954.05 | 563.50 |
| 2015-12-31 | 5,850.20 | 1,405.60 | 896.90 | 513.20 |
| 2015-09-30 | 5,654.40 | 1,392.30 | 841.35 | 487.95 |
| 2015-06-30 | 5,458.60 | 1,379.00 | 785.80 | 462.70 |
| 2015-03-31 | 5,481.65 | 1,366.25 | 767.65 | 466.60 |
| 2014-12-31 | 5,504.70 | 1,353.50 | 749.50 | 470.50 |
| 2014-09-30 | 5,419.75 | 1,330.25 | 773.05 | 468.45 |
| 2014-06-30 | 5,334.80 | 1,307.00 | 796.60 | 466.40 |
| 2014-03-31 | 5,188.55 | 1,269.75 | 803.30 | 466.15 |
| 2013-12-31 | 5,042.30 | 1,232.50 | 810.00 | 465.90 |
| 2013-09-30 | 4,996.35 | 1,221.95 | 806.15 | 446.35 |
| 2013-06-30 | 4,950.40 | 1,211.40 | 802.30 | 426.80 |
| 2013-03-31 | 4,862.55 | 1,177.80 | 795.15 | 409.65 |
| 2012-12-31 | 4,774.70 | 1,144.20 | 788.00 | 392.50 |
| 2012-09-30 | 4,695.55 | 1,084.05 | 765.75 | 381.10 |
| 2012-06-30 | 4,616.40 | 1,023.90 | 743.50 | 369.70 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- CSL has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
- CSL used its assets more efficiently than the Global Biotechs industry average last year based on Return on Assets.
- CSL's use of capital has not improved over the past 3 years (Return on Capital Employed).
Past performance checks
We assess CSL's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
CSL has a total score of 4/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
CSL Health
How is CSL's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up CSL's finances.
The net worth of a company is the difference between its assets and liabilities.
- CSL is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- CSL's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- High level of physical assets or inventory.
- Debt is covered by short term assets, assets are 1.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from CSL Company Filings, last reported 3 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 4,852.10 | 4,648.50 | 668.70 |
| 2018-09-30 | 4,852.10 | 4,648.50 | 668.70 |
| 2018-06-30 | 4,079.90 | 4,386.30 | 816.30 |
| 2018-03-31 | 4,079.90 | 4,386.30 | 816.30 |
| 2017-12-31 | 3,843.00 | 4,452.90 | 849.70 |
| 2017-09-30 | 3,843.00 | 4,452.90 | 849.70 |
| 2017-06-30 | 3,163.80 | 3,975.20 | 849.70 |
| 2017-03-31 | 3,163.80 | 3,975.20 | 849.70 |
| 2016-12-31 | 2,906.80 | 3,529.00 | 890.00 |
| 2016-09-30 | 2,906.80 | 3,529.00 | 890.00 |
| 2016-06-30 | 2,567.20 | 3,143.30 | 557.20 |
| 2016-03-31 | 2,567.20 | 3,143.30 | 557.20 |
| 2015-12-31 | 2,846.70 | 3,074.40 | 1,092.10 |
| 2015-09-30 | 2,846.70 | 3,074.40 | 1,092.10 |
| 2015-06-30 | 2,746.90 | 2,280.90 | 559.40 |
| 2015-03-31 | 2,746.90 | 2,280.90 | 559.40 |
| 2014-12-31 | 2,998.10 | 2,330.10 | 1,060.90 |
| 2014-09-30 | 2,998.10 | 2,330.10 | 1,060.90 |
| 2014-06-30 | 3,162.00 | 1,890.30 | 609.00 |
| 2014-03-31 | 3,162.00 | 1,890.30 | 609.00 |
| 2013-12-31 | 3,292.60 | 1,791.90 | 696.90 |
| 2013-09-30 | 3,292.60 | 1,791.90 | 696.90 |
| 2013-06-30 | 3,017.70 | 1,678.90 | 762.70 |
| 2013-03-31 | 3,017.70 | 1,678.90 | 762.70 |
| 2012-12-31 | 3,511.70 | 1,127.80 | 758.60 |
| 2012-09-30 | 3,511.70 | 1,127.80 | 758.60 |
| 2012-06-30 | 3,476.70 | 1,289.60 | 1,173.20 |
- CSL's level of debt (95.8%) compared to net worth is high (greater than 40%).
- The level of debt compared to net worth has increased over the past 5 years (54.5% vs 95.8% today).
- Debt is well covered by operating cash flow (34.4%, greater than 20% of total debt).
- Interest payments on debt are well covered by earnings (EBIT is 23.4x coverage).
Financial health checks
We assess CSL's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) CSL has a total score of 4/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
CSL Dividends
What is CSL's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
A$2,000 of
CSL
shares you are expected to receive
A$26
in your first year as a dividend.
Dividend Amount
- CSL's pays a lower dividend yield than the bottom 25% of dividend payers in Australia (2.52%).
- CSL's dividend is below the markets top 25% of dividend payers in Australia (5.81%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 12 Analyst Estimates (S&P Global) | See Below |
| Global Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 20 Stocks | 2.5% |
| Australia Market Average Dividend Yield | Market Cap Weighted Average of 417 Stocks | 4.3% |
| Australia Minimum Threshold Dividend Yield | 10th Percentile | 1.6% |
| Australia Bottom 25% Dividend Yield | 25th Percentile | 2.5% |
| Australia Top 25% Dividend Yield | 75th Percentile | 5.8% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-06-30 | 2.82 | 1.00 |
| 2022-06-30 | 2.43 | 2.00 |
| 2021-06-30 | 2.28 | 11.00 |
| 2020-06-30 | 2.09 | 13.00 |
| 2019-06-30 | 1.86 | 13.00 |
| Date (Data in $) | Dividend per share (annual) | Avg. Yield (%) |
|---|---|---|
| 2019-02-12 | 1.780 | 1.289 |
| 2018-08-14 | 1.860 | 1.334 |
| 2018-02-13 | 1.510 | 1.126 |
| 2017-08-15 | 1.360 | 1.256 |
| 2016-08-16 | 1.260 | 1.449 |
| 2016-02-15 | 1.240 | 1.531 |
| 2015-08-11 | 1.240 | 1.803 |
| 2014-09-05 | 1.297 | 1.869 |
| 2014-08-12 | 1.200 | 1.777 |
| 2014-02-11 | 1.060 | 1.660 |
| 2013-09-05 | 0.992 | 1.690 |
| 2013-08-13 | 1.020 | 1.695 |
| 2013-02-13 | 0.850 | 1.566 |
| 2012-08-21 | 0.845 | 1.700 |
| 2011-08-17 | 0.755 | 2.408 |
| 2010-08-18 | 0.704 | 2.358 |
| 2010-02-17 | 0.612 | 2.219 |
| 2009-08-19 | 0.661 | 2.498 |
| 2009-04-24 | 0.423 | 1.928 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- CSL is not paying a notable dividend for Australia, therefore no need to check if the payments are stable.
- CSL is not paying a notable dividend for Australia, therefore no need to check if the payments are increasing.
Income/ dividend checks
We assess CSL's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can CSL afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) CSL has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
CSL Management
CEO
| COMPENSATION | $11,266,445 |
| AGE | 61 |
| TENURE AS CEO | 5.8 years |
CEO Bio
Mr. Paul R. Perreault, BA (Psychology) has been the Chief Executive Officer and Managing Director of CSL Limited since July 1, 2013. Mr. Perreault serves as the Chief Executive Officer and Managing Director of CSL Behring LLC. He has more than 30 years of healthcare industry experience. He served as the President of CSL Behring UK Limited. He was responsible for all sales, marketing and commercial development activities at CSL Behring. Mr. Perreault served as an Executive Vice President of Commercial Operations at CSL Biotherapies, Inc. He served as the President of CSL Behring GmbH at CSL Ltd. since July 1, 2011. Mr. Perreault served as the President of CSL Behring LLC. He served as an Executive Vice President of Commercial Operations at CSL Ltd. Mr. Perreault served as an Executive Vice President of Worldwide Commercial Operations of CSL Behring LLC. Previously, he served as Vice President and General Manager of the U.S. Commercial Operations at CSL Behring LLC and was responsible for all sales, marketing, medical affairs, training and development, compliance and HR activities within the territory. He joined a CSL predecessor company in 1997 and has held senior roles in sales, marketing and operations. Prior to CSL Behring, he served as Vice President and General Manager of Plasma Operations of Aventis Bio-Services, where he oversaw all plasma operations and compliance initiatives at 79 plasma collection centers in the United States. He managed the Environmental Health and Safety team and the Corporate Marketing Department. Additionally, he served as Vice President and General Manager of the Aventis Behring Hospital Products Business Unit in North America and Puerto Rico. He worked for Wyeth-Ayerst Laboratories for 16 years in various key positions, including Area Business Director, Manager of Marketing Programs and District Sales Manager. He served at Centeon. He has been an Executive Director of CSL Limited since February 13, 2013. He was previously Chairman of the Global Board for the Plasma Protein Therapeutics Association. Mr. Perreault holds BA in Psychology from the University of Central Florida and completed advanced business management training at the Kellogg and Wharton schools of business. He also completed the CSL Executive Leadership program.
CEO Compensation
- Paul's compensation has increased by more than 20% in the past year.
- Paul's remuneration is higher than average for companies of similar size in Australia.
Management Team Tenure
Average tenure and age of the CSL management team in years:
- The tenure for the CSL management team is about average.
Management Team
Paul Perreault
MD, CEO & Executive Director
$11M
61
5.8 yrs
David Lamont
Chief Financial Officer
$3M
52
3.3 yrs
Robert Cuthbertson
Chief Scientific Officer & Director of R&D and Director
$3M
63
19.3 yrs
Greg Boss
Executive VP of Legal & Group General Counsel
$2M
57
Elizabeth Walker
Executive VP & Chief Human Resources Officer
$869K
48
1.3 yrs
Karen Etchberger
Executive Vice President of Quality & Business Services
$2M
60
9 yrs
Val Romberg
Executive Vice President of Manufacturing & Planning
$3M
60
4.3 yrs
Bill Campbell
Executive VP & Chief Commercial Officer
$2M
59
1.6 yrs
Gordon Naylor
President of Seqirus
$4M
55
3.3 yrs
Mark Dehring
Vice President of Investor Relations
Board of Directors Tenure
Average tenure and age of the CSL board of directors in years:
- The tenure for the CSL board of directors is about average.
Board of Directors
Brian McNamee
Chairman
$70K
61
0.5 yrs
Paul Perreault
MD, CEO & Executive Director
$11M
61
6.2 yrs
Robert Cuthbertson
Chief Scientific Officer & Director of R&D and Director
$3M
63
0.5 yrs
Bruce Brook
Independent Non-Executive Director
$206K
63
7.7 yrs
Megan Clark
Non Executive Director
$213K
59
3.2 yrs
Christine O’Reilly
Independent Non-Executive Director
$208K
57
8.2 yrs
Marie McDonald
Independent Non-Executive Director
$194K
62
5.7 yrs
Tadataka Yamada
Non Executive Director
$186K
72
2.6 yrs
Shah Hussain
Non Executive Director
$78K
53
1.2 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (A$) | Value (A$) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 04. Nov 18 | Sell | The Vanguard Group, Inc. | Company | 05. Jul 18 | 25. Oct 18 | -29,239 | A$229.32 | A$-6,704,978 | ||
| 04. Nov 18 | Buy | The Vanguard Group, Inc. | Company | 03. Jul 18 | 31. Oct 18 | 972,363 | A$230.28 | A$223,187,934 | ||
| 31. Oct 18 | Buy | Megan Clark | Individual | 29. Oct 18 | 29. Oct 18 | 220 | A$179.86 | A$39,569 | ||
| 27. Aug 18 | Buy | Shah Hussain | Individual | 21. Aug 18 | 21. Aug 18 | 24 | A$215.75 | A$5,178 | ||
| 27. Aug 18 | Buy | Marie McDonald | Individual | 21. Aug 18 | 21. Aug 18 | 24 | A$215.75 | A$5,178 | ||
| 27. Aug 18 | Buy | Christine O’Reilly | Individual | 21. Aug 18 | 21. Aug 18 | 24 | A$215.75 | A$5,178 | ||
| 27. Aug 18 | Buy | John Shine | Individual | 21. Aug 18 | 21. Aug 18 | 79 | A$215.75 | A$17,044 | ||
| 27. Aug 18 | Buy | Bruce Brook | Individual | 21. Aug 18 | 21. Aug 18 | 24 | A$215.75 | A$5,178 | ||
| 27. Aug 18 | Buy | Brian McNamee | Individual | 21. Aug 18 | 21. Aug 18 | 24 | A$215.75 | A$5,178 | ||
| 27. Aug 18 | Buy | Tadataka Yamada | Individual | 21. Aug 18 | 21. Aug 18 | 26 | A$215.75 | A$5,610 | ||
| 27. Aug 18 | Buy | Megan Clark | Individual | 21. Aug 18 | 21. Aug 18 | 24 | A$215.75 | A$5,178 | ||
| 27. Aug 18 | Buy | David Anstice | Individual | 21. Aug 18 | 21. Aug 18 | 30 | A$215.75 | A$6,473 | ||
| 10. May 18 | Buy | Megan Clark | Individual | 07. May 18 | 07. May 18 | 290 | A$171.79 | A$49,819 | ||
Management checks
We assess CSL's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) CSL has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
CSL News
Simply Wall St News
Should You Be Tempted To Sell CSL Limited (ASX:CSL) Because Of Its P/E Ratio?
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). … How Do I Calculate CSL's Price To Earnings Ratio … Price to Earnings Ratio = Share Price (in reporting currency) ÷ Earnings per Share (EPS)
Simply Wall St - – Full articleIs CSL Limited (ASX:CSL) Excessively Paying Its CEO?
This analysis aims first to contrast CEO compensation with other large companies. … How Does Paul Perreault's Compensation Compare With Similar Sized Companies. … Our data indicates that CSL Limited is worth AU$91b, and total annual CEO compensation is US$11m.
Simply Wall St - – Full articleWhat Should We Expect From CSL Limited's (ASX:CSL) Earnings In The Year Ahead?
Since CSL Limited (ASX:CSL) released its earnings in December 2018,. … with profits predicted to increase by 12% next year … the past 5-year average growth rate of 6.4%
Simply Wall St - – Full articleIf You Had Bought CSL (ASX:CSL) Stock Five Years Ago, You Could Pocket A 176% Gain Today
One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). … Over half a decade, CSL managed to grow its earnings per share at 9.6% a year. … Dive deeper into the earnings by checking this interactive graph of CSL's earnings, revenue and cash flow.
Simply Wall St - – Full articleCSL Limited (ASX:CSL) Delivered A Better ROE Than Its Industry
This article is for those who would like to learn about Return On Equity (ROE). … That means that for every A$1 worth of shareholders' equity, it generated A$0.37 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity
Simply Wall St - – Full articleIs CSL Limited (ASX:CSL) A Financially Sound Company?
the key to their continued success lies in its financial health. … Let’s take a look at CSL’s leverage and assess its financial strength to get an idea of their ability to fund strategic acquisitions and grow through cyclical pressures. … Remember this is a very top-level look that focuses exclusively on financial health, so I recommend a deeper analysis
Simply Wall St - – Full articleHow Much Of CSL Limited (ASX:CSL) Do Institutions Own?
Conversely, insiders often decrease their ownership over time. … We also tend to see lower insider ownership in companies that were previously publicly owned. … Taking a look at the our data on the ownership groups (below), it's seems that.
Simply Wall St - – Full articleDespite Its High P/E Ratio, Is CSL Limited (ASX:CSL) Still Undervalued?
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). … Price to Earnings Ratio = Share Price (in reporting currency) ÷ Earnings per Share (EPS) … P/E of 36.78 = $140.59 (Note: this is the share price in the reporting currency, namely, USD ) ÷ $3.82
Simply Wall St - – Full articleDoes CSL Limited's (ASX:CSL) CEO Pay Compare Well With Peers?
This analysis aims first to contrast CEO compensation with other large companies. … How Does Paul Perreault's Compensation Compare With Similar Sized Companies. … According to our data, CSL Limited has a market capitalization of AU$85b, and pays its CEO total annual compensation worth US$11m.
Simply Wall St - – Full articleKnow This Before Buying CSL Limited (ASX:CSL) For Its Dividend
Dividends play an important role in compounding returns in the long run and end up forming a sizeable part of investment returns. … Historically, CSL Limited (ASX:CSL) has been paying a dividend to shareholders. … 5 checks you should use to assess a dividend stock
Simply Wall St - – Full articleCSL Company Info
Description
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. It also operates approximately 140 plasma collection centers. In addition, this segment conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and developsinfluenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Details
| Name: | CSL Limited |
| CSL | |
| Exchange: | ASX |
| Founded: | 1916 |
| A$86,320,276,272 | |
| 453,101,025 | |
| Website: | http://www.csl.com |
| Address: |
CSL Limited 45 Poplar Road, Parkville, Victoria, 3052, Australia |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| ASX | CSL | Ordinary Shares | Australian Securities Exchange | AU | AUD | 02. Jun 1994 | |
| OTCPK | CMXH.F | Ordinary Shares | Pink Sheets LLC | US | USD | 02. Jun 1994 | |
| DB | CSJ | Ordinary Shares | Deutsche Boerse AG | DE | EUR | 02. Jun 1994 | |
| CHIA | CSL | Ordinary Shares | Chi-X Australia | AU | AUD | 02. Jun 1994 | |
| OTCPK | CSLL.Y | SPON ADR EACH REPR 0.5 ORD | Pink Sheets LLC | US | USD | 16. Oct 2008 | |
| DB | CSJA | SPON ADR EACH REPR 0.5 ORD | Deutsche Boerse AG | DE | EUR | 16. Oct 2008 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/04/23 10:31 |
| End of day share price update: | 2019/04/23 00:00 |
| Last estimates confirmation: | 2019/04/17 |
| Last earnings filing: | 2019/02/12 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/06/30 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
